4 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
will split global development costs for seralutinib, except for the PROSERA Study, for which Gossamer will remain solely responsible. Gossamer remains
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
GOSS
6 May 24
financially responsible.
In the U.S., the companies will evenly share commercial profits and losses.
Gossamer
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
GOSS
6 May 24
to the PROSERA Study, for which Gossamer will remain financially responsible. In the US, the companies will evenly share commercial profits and losses
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
to the PROSERA Study, for which Gossamer will remain financially responsible. In the US, the companies will evenly share commercial profits and losses
- Prev
- 1
- Next